Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), Marvel wishes to announce that it has amended the conversation price for the Debentures, which are convertible at the holder's option into Common Shares, to a conversion price of $0.17 per Common Share. All other terms of the Debenture and of the Offering remain unchanged and the Offering remains subject to approval of the TSX Venture Exchange.